129 related articles for article (PubMed ID: 2293406)
1. Nonlinear kinetics of imipramine in low and medium plasma level ranges.
Sindrup SH; Brøsen K; Gram LF
Ther Drug Monit; 1990 Sep; 12(5):445-9. PubMed ID: 2293406
[TBL] [Abstract][Full Text] [Related]
2. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Brøsen K; Gram LF
Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
[TBL] [Abstract][Full Text] [Related]
3. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
4. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
5. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms.
Sindrup SH; Gram LF; Skjold T; Frøland A; Beck-Nielsen H
Clin Pharmacol Ther; 1990 Apr; 47(4):509-15. PubMed ID: 2328559
[TBL] [Abstract][Full Text] [Related]
6. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
7. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF
Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
[TBL] [Abstract][Full Text] [Related]
9. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
10. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
Sindrup SH; Gram LF; Skjold T; Grodum E; Brøsen K; Beck-Nielsen H
Br J Clin Pharmacol; 1990 Nov; 30(5):683-91. PubMed ID: 2271367
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of imipramine and desipramine in man after different routes of administration.
Nagy A; Johansson R
Naunyn Schmiedebergs Arch Pharmacol; 1975; 290(2-3):145-60. PubMed ID: 1102994
[TBL] [Abstract][Full Text] [Related]
12. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.
Brøsen K; Gram LF; Klysner R; Bech P
Eur J Clin Pharmacol; 1986; 30(1):43-9. PubMed ID: 3709631
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Spina E; Pollicino AM; Avenoso A; Campo GM; Perucca E; Caputi AP
Ther Drug Monit; 1993 Jun; 15(3):243-6. PubMed ID: 8333005
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics.
Koyama E; Kikuchi Y; Echizen H; Chiba K; Ishizaki T
Ther Drug Monit; 1993 Jun; 15(3):224-35. PubMed ID: 8333003
[TBL] [Abstract][Full Text] [Related]
15. Single-dose kinetics predict steady-state concentrations on imipramine and desipramine.
Potter WZ; Zavadil AP; Kopin IJ; Goodwin FK
Arch Gen Psychiatry; 1980 Mar; 37(3):314-20. PubMed ID: 7362419
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of monitoring serum levels of imipramine and desipramine in patients treated for endogenous depression].
Szymura-Oleksiak J; Wasieczko A
Psychiatr Pol; 1991; 25(1):54-60. PubMed ID: 1780375
[TBL] [Abstract][Full Text] [Related]
17. Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time.
Ziegler VE; Biggs JT; Rosen SH; Meyer DA; Preskorn SH
J Clin Psychiatry; 1978 Aug; 39(8):660-3. PubMed ID: 681303
[TBL] [Abstract][Full Text] [Related]
18. The relationship between paroxetine and the sparteine oxidation polymorphism.
Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
[TBL] [Abstract][Full Text] [Related]
19. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
20. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
Madsen H; Hansen TS; Brøsen K
Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
